medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Número 6

<< Anterior Siguiente >>

Ann Hepatol 2018; 17 (6)


Drug-Drug Interactions in Hepatitis Patients: Do these Interactions Matter in Clinical Perspectives?

Noor S, Ismail M, Haider I, Khadim F

Idioma: Ingles.
Referencias bibliográficas: 36
Paginas: 1001-1011
Archivo PDF: 214.57 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sembulingam K, Sembulingam P. (eds.) Essentials of Medical Phsyiology. 2nd Ed. New Dehli, India: Jaypee Brothers Medical Publishers, 2012; pp. 179-88.

  2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.

  3. Delco F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S. Dose adjustment in patients with liver disease. Drug Saf 2005; 28: 529-45.

  4. Blaschke TF, Rubin PC. Hepatic first-pass metabolism in liver disease. Clin Pharmacokinet 1979; 4: 423-32.

  5. Vyas K, Gala B, Sawant P, Das HS, Kulhalli PM, Mahajan SS. Assessment of portal hemodynamics by ultrasound color Doppler and laser Doppler velocimetry in liver cirrhosis. Indian J Gastroenterol 2001; 21: 176-8.

  6. Adedoyin A, Arns PA, Richards WO, Wilkinson GR, Branch RA. Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther 1998; 64: 8-17.

  7. Wioeniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drugdrug interactions and QT prolongation as a commonly assessed cardiac effect-comprehensive overview of clinical trials. BMC Pharmacol Toxicol 2016; 17: 12.

  8. Ginès P, Arrovo V, Rodés J. Pharmacotherapy of ascites associated with cirrhosis. Drugs 1992; 43: 316-32.

  9. Patel N, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt L-A, Miller C. A cross-sectional study comparing the frequency of drug interactions after adding simeprevir-or sofosbuvir-containing therapy to medication profiles of hepatitis C monoinfected patients. Infect Dis Ther 2015; 4: 67-78.

  10. Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol 2014; 26: 1073-82.

  11. Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, Klinker H, et al. Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions. J Hepatol 2013; 58: 792-800.

  12. Franz CC, Egger S, Born C, Bravo AER, Krähenbühl S. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol 2012; 68: 179-88.

  13. Back D, Else L. The importance of drug–drug interactions in the DAA era. Dig Liver Dis 2013; 45: S343-S348.

  14. Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, et al. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One 2017; 12: e0172159.

  15. Poizot-Martin I, Naqvi A, Obry-Roguet V, Valantin M-A, Cuzin L, Billaud E, Cheret A, et al. Potential for drug-drug interactions between antiretrovirals and HCV direct acting antivirals in a large cohort of HIV/HCV coinfected patients. PLoS One 2015; 10: e0141164.

  16. Micromedex Drug-Reax®, Greenwood Village, CO: Truven Health Analytics. Available at: https:// www.micromedexsolutions.com/micromedex2/librarian/ssl/ true. Accessed February 10 2017.

  17. Patel RI, Beckett RD. Evaluation of resources for analyzing drug interactions. J Med Libr Assoc 2016; 104: 290-5.

  18. Kheshti R, Aalipour M, Namazi S. A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract 2016; 5: 257-63.

  19. Tatro DS. (ed.) Drug Interaction Facts: Facts and Comparisons. St. Louis, Missouri: Wolters Kluwer Health, 2008; pp. 901-1358.

  20. Baxter K. (ed.) Stockley’s Drug Interactions. 9th ed. London, Chicago: Pharmaceutical Press; 2010; pp.349-1123.

  21. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med 2008; 19: 413-20.

  22. Ibáñez A, Alcalá M, García J, Puche E. Drug-drug interactions in patients from an internal medicine service. Farm Hosp 2008; 32: 293-297.

  23. Ismail M, Iqbal Z, Khattak MB, Khan MI, Arsalan H, Javaid A, Gul Q, et al. Potential drug–drug interactions in internal medicine wards in hospital setting in Pakistan. Int J Clin Pharm 2013; 35: 455-62.

  24. Ismail M, Aziz S, Noor S, Haider I, Shams F, Haq I, Khadim F, et al. Potential drug-drug interactions in pediatric patients admitted to intensive care unit of Khyber Teaching Hospital, Peshawar, Pakistan: A cross-sectional study. J Crit Care 2017; 40: 243-50.

  25. Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World J Gastroenterol 2017; 23: 1618-26.

  26. Moura CS, Prado NM, Belo NO, Acurcio FA. Evaluation of drug–drug interaction screening software combined with pharmacist intervention. Int J Clin Pharm 2012; 34: 547-52.

  27. Geerts AF, De Koning FH, De Smet PA, Van Solinge WW, Egberts TC. Laboratory tests in the clinical risk management of potential drug-drug interactions. Drug Saf 2009; 32: 1189- 97.

  28. van Roon EN, Flikweert S, le Comte M, Langendijk PN, Kwee- Zuiderwijk WJ, Smits P, Brouwers JR. Clinical relevance of drug-drug interactions. Drug Saf 2005; 28: 1131-9.

  29. Egger SS, Drewe J, Schlienger RG. Potential drug–drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003; 58: 773-8.

  30. Boccaccio V, Bruno S. Optimal management of patients with chronic hepatitis C and comorbidities. Liver Int 2015; 35: 35- 43.

  31. Moura CSd, Acurcio FdA, Belo NdO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharmaceut Sci 2009; 12: 266-72.

  32. Caratozzolo S, Gipponi S, Marengoni A, Pari E, Scalvini A, Pasina L, Magoni M, et al. Potentially Serious Drug-Drug Interactions in Older Patients Hospitalized for Acute Ischemic and Hemorrhagic Stroke. Eur Neurol 2016; 76: 161-6.

  33. Gagne J, Maio V, Rabinowitz C. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharm Ther 2008; 33: 141-51.

  34. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 2002; 40: 1161-71.

  35. Roberts JS, Watrous ML, Schulz RM, Mauch RP, Nightengale BS. Quantifying the Clinical Significance of Drug—Drug Interactions: Scaling Pharmacists’ Perceptions of a Common Interaction Classification Scheme. Ann Pharmacother 1996; 30: 926-34.

  36. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993; 9: 51-9.




2020     |     www.medigraphic.com